-
Aurinia Pharmaceuticals NASDAQ:AUPH Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
Location: 1203-4464 Markham St, British Columbia, V8Z 7X8, Canada | Website: www.auriniapharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
826.7M
Cash
330.3M
Avg Qtr Burn
-430K
Short % of Float
5.59%
Insider Ownership
7.07%
Institutional Own.
44.47%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lupkynis (Voclosporin) Details Lupus nephritis | Approved Quarterly sales | |
AUR200 Details Autoimmune disease | Phase 1 Data readout | |
Voclosporin Ophthalmic Solution Details Dry eye syndrome | Failed Discontinued | |
Voclosporin Details Focal segmental glomerulosclerosis | Failed Discontinued |